Description: GlaxoSmithKline plc, together with its subsidiaries, discovers, develops, manufactures, and markets pharmaceutical products, over-the-counter medicines, and health-related consumer products worldwide. It offers pharmaceutical products in various therapeutic areas comprising respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, antibacterials, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. The company provides prescription medicines to treat a range of conditions, including infections, depression, skin conditions, asthma, heart and circulatory disease, and cancer. It also produces paediatric and adult vaccines to prevent a range of infectious diseases, including hepatitis A and B; diphtheria, tetanus, and whooping cough; measles, mumps, and rubella; polio; typhoid; influenza; and bacterial meningitis. In addition, it provides consumer health products in oral care, nutritional, total wellness, and skin health areas. The company's total wellness products include Panadol for the treatment of paracetamol-based treatment of headache and joint pain, fever, and cold symptoms; NicoDerm, NiQuitin CQ, and Nicabate for the treatment of nicotine withdrawal as an aid to quitting smoking; ENO Tums, a rapid relief antacid; and oral care products comprise Sensodyne for the prevention of dental sensitivity; Polident, Poligrip, and Corega to improve comfort of fitted dentures and to clean dentures; Aquafresh for the prevention of caries, gum disease, and bad breath; and Parodontax to help stop bleeding gums and gum health. Its nutrition products include Lucozade for energy and hydration; and Horlicks and Maxinutrition for nutrition; and skin health products comprise Physiogel, a face and body care product for dry, sensitive, and irritated skin, and Oilatum, a soothing treatment for eczema and dry skin conditions. The company was founded in 1935 and is headquartered in Brentford, the United Kingdom.
Home Page: www.gsk.com
GSK Technical Analysis
980 Great West Road
Brentford,
TW8 9GS
United Kingdom
Phone:
44 20 8047 5000
Officers
| Name | Title |
|---|---|
| Ms. Emma Natasha Walmsley | CEO & Director |
| Mr. Iain James Mackay | CFO & Exec. Director |
| Ms. Julie Brown | Chief Financial Officer |
| Ms. Shobie Ramakrishnan | Chief Digital & Technology Officer |
| Mr. Tony Wood | Chief Scientific Officer |
| Ms. Sarah Elton-Farr | Head of Investor Relations |
| Mr. James Ford | Sr. VP & Group Gen. Counsel of Legal & Compliance |
| Ms. Sally Jackson | Sr. VP of Global Communications & CEO Office |
| Ms. Diana Conrad | Chief People Officer |
| Mr. David Simon Redfern | Chief Strategy Officer |
Exchange: NYSE
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 9.8039 |
|---|---|
| Trailing PE: | 13.3 |
| Price-to-Book MRQ: | 6.5494 |
| Price-to-Sales TTM: | 1.8639 |
| IPO Date: | 1986-07-09 |
| Fiscal Year End: | December |
| Full Time Employees: | 90096 |